spp-11 Antibody

What is the SP11 antibody and what target does it recognize?

The SP11 antibody is a rabbit monoclonal antibody that specifically recognizes Synaptophysin, a major synaptic vesicle protein (p38) involved in the regulation of both short-term and long-term synaptic plasticity. This antibody clone has been validated and utilized in research since 2005, establishing it as a reliable marker for synaptic terminals . Synaptophysin plays critical roles in organizing membrane components and targeting vesicles to the plasma membrane, making it an essential protein for studying neuronal connectivity and function .

What are the primary applications for SP11 antibody in neuroscience research?

SP11 antibody has been extensively validated for multiple applications essential to neuroscience research:

• Western blotting for protein expression quantification

• Immunohistochemistry (IHC) for tissue localization studies

• Immunofluorescence for high-resolution imaging of synaptic structures

This versatility makes it particularly valuable for studies investigating synaptic density, neuronal connectivity, and neurodegenerative conditions affecting synaptic integrity.

What species reactivity has been confirmed for SP11 antibody?

The SP11 antibody clone has been definitively confirmed for reactivity with human and rat samples . This cross-species applicability is particularly valuable for translational research where findings in rodent models need to be validated in human tissues. The antibody has been successfully applied to primary hippocampal rat neurons/glia, demonstrating its utility in cellular neuroscience applications .

What sample preparation methods optimize SP11 antibody performance in immunofluorescence?

For optimal immunofluorescence results with SP11 antibody, the following sample preparation protocol has been validated:

• Fixation with 100% methanol for 5 minutes

• Permeabilization with 0.1% PBS-Triton X-100 for 5 minutes

• Blocking with 1% BSA/10% normal goat serum/0.3M glycine in 0.1% PBS-Tween for 1 hour

• Overnight incubation with primary antibody at 4°C

This protocol has been specifically validated for primary hippocampal neurons at DIV14, ensuring preservation of the Synaptophysin epitope while minimizing background staining.

How does SP11 compare with other Synaptophysin antibodies for research applications?

While the search results don't provide direct comparative data with other Synaptophysin antibodies, SP11's status as a monoclonal antibody offers several advantages:

• Higher specificity compared to polyclonal alternatives

• Consistent lot-to-lot reproducibility

• Reduced background staining

• Recognition of a single epitope, enabling more precise analyses

These properties make SP11 particularly valuable for quantitative studies where precision and reproducibility are essential.

What controls should be implemented when validating SP11 antibody in a new experimental system?

When implementing SP11 antibody in a new experimental system, the following controls should be included:

• Positive control: Known Synaptophysin-expressing tissues/cells (e.g., hippocampal neurons)

• Negative control: Non-neuronal tissues with minimal Synaptophysin expression

• Antibody omission control: Primary antibody replaced with diluent

• Isotype control: Matched concentration of irrelevant rabbit monoclonal IgG

• Knockdown/knockout validation: When possible, tissues/cells with Synaptophysin suppression

These controls help establish the specificity and sensitivity of the antibody in your particular experimental conditions.

How can SP11 antibody be optimized for multiplex immunofluorescence studies?

For multiplex immunofluorescence studies with SP11 antibody, researchers should consider:

• Antibody sequencing: Apply SP11 in the appropriate order within your staining protocol based on host species and detection system compatibility

• Cross-reactivity prevention: Use sequential rather than simultaneous staining when antibodies are from the same host species

• Signal separation: Carefully select fluorophores with minimal spectral overlap

• Epitope retrieval compatibility: Ensure that all antibodies in the multiplex panel perform optimally under the same retrieval conditions

When detecting multiple synaptic proteins, timing between antibody applications should be optimized to prevent steric hindrance, which can occur when target epitopes are in close proximity at synaptic junctions.

What modifications are needed for quantitative analyses of synaptic density using SP11?

For quantitative analyses of synaptic density using SP11 antibody, consider these methodological adaptations:

• Standardized acquisition: Use consistent microscope settings (exposure, gain, offset) between samples

• Sampling strategy: Implement systematic random sampling across brain regions

• Z-stack imaging: Capture complete synaptic structures through 3D imaging

• Thresholding method: Apply consistent and objective thresholding algorithms

This approach allows for reliable quantification of synaptic changes in experimental versus control conditions.

How can SP11 antibody be utilized in studying neurodegenerative disease models?

SP11 antibody is valuable for investigating synaptic loss in neurodegenerative disease models through:

• Temporal analysis: Tracking Synaptophysin levels at different disease stages

• Regional vulnerability: Comparing affected versus spared brain regions

• Treatment response: Measuring synaptic restoration following intervention

• Correlation studies: Linking synaptic markers with functional outcomes or other pathological markers

These applications can reveal disease mechanisms where synaptic dysfunction precedes neuronal death, potentially identifying therapeutic windows for intervention.

What are common causes of high background when using SP11 antibody?

When encountering high background with SP11 antibody, consider these potential causes and solutions:

• Insufficient blocking: Increase blocking time or adjust blocking agent concentration

• Suboptimal antibody concentration: Titrate primary antibody to determine optimal working dilution

• Excessive permeabilization: Reduce detergent concentration or exposure time

• Non-specific binding: Include protein blockers (e.g., BSA, serum) in antibody diluent

• Inadequate washing: Increase number and duration of wash steps

Starting with a higher dilution (1:500) and adjusting based on signal-to-noise ratio is often an effective approach.

How can inconsistent staining patterns with SP11 antibody be resolved?

Inconsistent staining patterns may result from several factors that can be systematically addressed:

• Variable fixation: Standardize fixation protocol including duration, temperature, and fixative composition

• Antigen masking: Optimize antigen retrieval methods (heat-induced versus enzymatic)

• Storage conditions: Ensure consistent antibody storage at recommended temperature

• Sample heterogeneity: Account for variations in Synaptophysin expression between brain regions

• Detection system variability: Use consistent secondary antibody lots and development times

Implementing a positive control slide in each experiment can help identify technical versus biological variability.

What analytical techniques can validate SP11 antibody specificity?

To validate SP11 antibody specificity, researchers should consider multiple complementary techniques:

• Western blotting: Confirm single band at expected molecular weight (38 kDa for Synaptophysin)

• Immunoprecipitation: Verify pull-down of the target protein

• Mass spectrometry: Analyze immunoprecipitated material to confirm identity

• Peptide competition: Demonstrate signal reduction with blocking peptide

• Surface Plasmon Resonance (SPR): Measure binding kinetics and affinity

These techniques provide comprehensive evidence of antibody specificity before proceeding with complex experimental applications.

How can SP11 antibody be adapted for super-resolution microscopy?

For super-resolution microscopy applications using SP11 antibody, consider these modifications:

• Secondary antibody selection: Use smaller probes (e.g., F(ab) fragments) or directly conjugated primary antibodies

• Sample preparation: Optimize fixation to preserve nanoscale structure while maintaining epitope accessibility

• Mounting media: Use media with appropriate refractive index and anti-fade properties

• Labeling density: Titrate antibody concentration to achieve optimal labeling density for the specific super-resolution technique (STED, STORM, PALM)

These adaptations enable visualization of synaptic substructures beyond the diffraction limit, revealing Synaptophysin distribution within individual synaptic vesicles.

What are the considerations for using SP11 in electron microscopy immunolabeling?

For electron microscopy applications with SP11 antibody:

• Embedding protocols: Use low-temperature embedding resins to preserve antigenicity

• Section thickness: Prepare ultrathin sections (70-90 nm) for optimal resolution

• Antibody penetration: Consider pre-embedding labeling for improved access to intracellular epitopes

• Gold conjugate size: Select appropriate gold particle size (typically 5-15 nm) based on resolution needs

• Double labeling: Pair with other synaptic markers using distinguishable gold sizes for colocalization studies

These approaches allow correlation between Synaptophysin localization and ultrastructural features of synapses.

How can SP11 antibody data be integrated with functional studies?

SP11 antibody data can be integrated with functional neuroscience approaches through:

• Electrophysiology correlation: Map Synaptophysin-positive terminals to recorded synaptic currents

• Activity-dependent labeling: Combine SP11 with activity markers (c-Fos, Arc) to link structure and function

• Live-dead applications: Use fixed-time-point SP11 staining to contextualize live calcium imaging data

• Behavioral correlations: Quantify Synaptophysin levels in relation to behavioral outcomes

This integration provides a more comprehensive understanding of how synaptic structure relates to neuronal function across different experimental paradigms.